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Michael C. O’Donovan, FRCPsych, PhD, Anita Thapar, FRCPsych, PhD, Peter Holmans, PhDObjective: Attention-deﬁcit/hyperactivity disorder (ADHD) and autism spectrum disorder
(ASD) often co-occur and share genetic risks. The aim of this analysis was to determine more
broadly whether ADHD and ASD share biological underpinnings. Method: We compared
copy number variant (CNV) data from 727 children with ADHD and 5,081 population controls
to data from 996 individuals with ASD and an independent set of 1,287 controls. Using pathway
analyses, we investigated whether CNVs observed in individuals with ADHD have an impact
on genes in the same biological pathways as on those observed in individuals with
ASD. Results: The results suggest that the biological pathways affected by CNVs in ADHD
overlap with those affected by CNVs in ASDmore than would be expected by chance. Moreover,
this was true even when speciﬁc CNV regions common to both disorders were excluded from the
analysis. After correction for multiple testing, genes involved in 3 biological processes (nicotinic
acetylcholine receptor signalling pathway, cell division, and response to drug) showed signiﬁcant
enrichment for case CNV hits in the combined ADHD and ASD sample. Conclusion: The
results of this study indicate the presence of signiﬁcant overlap of shared biological processes
disrupted by large rare CNVs in children with these 2 neurodevelopmental conditions. J. Am.
Acad. Child Adolesc. Psychiatry, 2014;53(7):761–770. Key Words: ADHD, ASD, pathway
analysis, CNVs, comorbidityttention-deﬁcit/hyperactivity disorder
(ADHD) and autism spectrum disorderA (ASD) show strong comorbidity at the
level of both symptoms and disorder.1,2 Although
ADHD and ASD are distinctive in terms of core
diagnostic symptoms, both have onset in early
childhood, present more commonly in males,
and are associated with similar cognitive, de-
velopmental, and neurological problems.3 Twin
studies have consistently shown that shared in-
herited factors explain a large proportion of the
comorbidity between ADHD and ASD, as well
as comorbidity with other neurodevelopmental
problems.4,5Supplemental material cited in this article is available online.
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ADHD and ASD have not been identiﬁed thus
far,6,7 this could reﬂect the relatively small sample
sizes in the genome-wide association studies
(GWAS) of each of these disorders. However,
recent studies have suggested that rare (<1%
frequency) chromosomal deletions and duplica-
tions, known as copy number variants (CNVs),
occurring in children with ADHD show signiﬁ-
cant overlap with those already implicated in
ASD.8-10 It is not yet known whether ADHD
and ASD also more broadly share biological
underpinnings.
In this study, we set out to investigate whether
large rare CNVs found in individuals with each
of these clinical phenotypes index disruption of
shared biological pathways in the disorders. The
ﬁrst aim was to determine whether biologicalY
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ADHD, as compared with ethnically matched
controls, showed statistically signiﬁcant enrich-
ment for CNV hits in participants with ASD, as
compared to a separate set of controls. The sec-
ond aim was to meta-analyze the ADHD and
ASD samples to increase the power of detecting
speciﬁc shared biological pathways disrupted in




The sample consisted of 799 young persons of white
ethnicity from Cardiff, Wales (n ¼ 559), St. Andrews,
Scotland (n ¼ 44), and Dublin, Ireland (n ¼ 196). All
children were recruited from community clinics and
had a diagnosis of DSM-IV/DSM-III-R ADHD or In-
ternational Statistical Classiﬁcation of Diseases and
Related Health Problems–Tenth Revision (ICD-10)
hyperkinetic disorder. Exclusion criteria were intel-
lectual disability (ID; IQ <70), major medical or neu-
rological conditions, ASD, psychosis, and bipolar
disorder. Approval was obtained from North West
England, Wales, National Health Service Tayside, and
Eastern Regional Health Authority research ethics
committees. Written informed consent was obtained
from parents, and assent/consent was gained from the
young persons.
Clinical Measures
ADHD and other psychiatric diagnoses were assessed
by trained psychologists using the Child and Adoles-
cent Psychiatric Assessment (CAPA) parent version,11
a semi-structured interview. Conﬁrmation of perva-
siveness of symptoms in school was obtained using the
Child Attention-Deﬁcit Hyperactivity Disorder Teacher
Telephone Interview (CHATTI)12 or the Conner’s
Teacher Questionnaire.13 The Wechsler Intelligence
Scale for Children–III/IV was used to assess IQ.14,15
The age range was 4 through 18 years, with a mean
age of 10 years 3 months (SD ¼ 3 years). The sample
was 87.4% male.
Genome-wide Data: Individuals With ADHD and
Controls
DNA for all participants with ADHD was extracted
from saliva or peripheral blood samples, as described
previously.16 Control genetic data were obtained from
the Wellcome Trust Case-Control Consortium–Phase 2
(WTCCC2).17 Quality control (QC) procedures and
CNV detection protocols were identical to those
described previously.16 Analysis was based on single
nucleotide polymorphisms (SNPs) that were present on
genotyping chips in both participants with ADHD and
controls. After QC, genome-wide data for 502,702 SNPsJOURN
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were used for analysis. Analyses of CNVs were limited
to those that were large (>500 kb) and rare (<1% fre-
quency in the combined group of participants with
ADHD and controls) because they have better con-
cordance across different genotyping platforms, are
determined with greater accuracy, and are more
robustly associated with neurodevelopmental disor-
ders.8 There were 78 large, rare CNVs within the con-
trol sample (as previously published16) and 85 from
participants with ADHD. Parental genotype data were
not available for most of the sample.
CNV Data: Individuals With ASD
CNVs for participants with ASD and independent
controls were obtained from the publicly available
supplementary data of a study comparing CNVs in 996
individuals of white ethnicity with ASD to 1,287
matched controls.18 In this dataset, ASD diagnosis was
conﬁrmed using the Autism Diagnostic Interview–
Revised (ADI-R) and Autism Diagnostic Observation
Schedule (ADOS).19,20 Control samples were obtained
from the Study on Addiction: Genetics and Environ-
ment (SAGE) and from HapMap CEPH Utah (HapMap
CEU).18,21 CNVs were selected if present at <1% fre-
quency in the total sample and having length >30kb,
giving a set of 5,478 CNVs, as described previously.18
This CNV set contains 215 CNVs >500 kb in controls
and 133 in participants with ASD. Of these 133 CNVs
in participants with ASD, 13 were de novo (i.e.,
conﬁrmed not to be transmitted from either parent)
and 120 were conﬁrmed to be inherited.
Method for Testing Pathway Enrichment
Pathways. The following 5 sets of pathways were used
in the enrichment analyses (the same as used previ-
ously16): Gene Ontology (GO),22 accessed November 8,
2011; Kyoto Encyclopedia of Genes and Genomes
(KEGG),23 accessed June 27, 2011; PANTHER (Protein
ANalysis THrough Evolutionary Relationships) path-
ways version 3.1,24 accessed February 1, 2012; Mouse
Genome Informatics (MGI) database,25 accessed March
7, 2012; and Canonical pathways (including REAC-
TOME and BIOCARTA) from Molecular Signatures
Database (MSigDB) v3.0,26 accessed February 1, 2011.
For reasons of power, analyses were restricted
to pathways containing between 3 and 1,500 genes
(16,569 in total). Furthermore, pathways required at
least 10 hits in the total sample to be counted (10,240
in total). This was to reduce the chance of small path-
ways showing apparent enrichment based on a small
number of CNV hits.
Testing Pathway Enrichment of Case CNV Hits. Each
CNV was assigned a binary variable (“participant” or
“control”) according to whether it came from a
participant with ADHD or ASD or from a control. A
CNV was considered to “hit” a gene if any part of the
CNV lay between the start and end points of theAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
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BIOLOGICAL OVERLAP OF ADHD AND ASDlongest transcript of the gene (as deﬁned by the Na-
tional Center for Biotechnology Information [NCBI]).
Both CNV and gene positions use build 36.3.
The following logistic regression model was ﬁtted to
the sample of CNVs for each pathway separately: par-
ticipants with ADHD or ASD/control w CNV length þ
number of genes hit outside pathway þ hit gene(s) in
pathway (yes/no), and the deviance was compared to the
following: participants with ADHD or ASD/control w
CNV length þ number of genes hit outside pathway to give
a (1-sided) test of enrichment of case CNV hits on genes
in the pathway.
This method is similar to that proposed by others27
and has been applied to de novo schizophrenia
CNVs.28
CNV length is ﬁtted in the model because long CNVs
are more likely to hit any set of genes than small ones,
and CNV length may differ systematically between
participants with ADHD or ASD and controls. The
number of genes hit outside pathway is ﬁtted to allow
for case CNVs inﬂuencing disease status by hitting
genes other than those in the pathway being tested. A
binary variable (yes/no) is used to indicate whether
a CNV hits gene(s) in a pathway rather than the number
of genes in the pathway hit by the CNV, to allow for
some pathways having several genes that are physi-
cally close together (and thus likely to be hit by the
same CNV).
The same analysis approach was also used to obtain
tests of gene-speciﬁc enrichment for participant CNV
hits, by deﬁning pathways containing single genes.
Primary Analyses. To test whether the pathways
with nominally signiﬁcant enrichment in the ADHD
sample showed greater than expected enrichment for
case CNV hits in the ASD sample, enrichment analyses
were run in the ASD sample restricted to the pathways
enriched at various levels (p < .05, p < .01, p < .001) in
the ADHD sample. The number of enriched pathways
in the ASD sample at the same signiﬁcance level as that
used to select pathways from the ADHD sample was
compared to that obtained when the participant/con-
trol labels were randomly permuted in the ASD sam-
ple. This procedure was repeated 1,000 times, and the
p value for the number of pathways signiﬁcantly
enriched in both samples was estimated as the pro-
portion of replicates, where the number of signiﬁcant-
ly enriched pathways was at least as great as that
observed in the actual data. This analysis allows for
overlap between pathways in terms of their gene
membership. Analyses were carried out using all
participants with ASD CNVs (versus control CNVs),
and also for de novo and inherited CNVs (versus all
control CNVs), separately.
A combined pathway enrichment analysis was
performed by meta-analyzing the ADHD and ASD
case CNVs compared to their corresponding control
CNVs. Enrichment p values for both genes andJOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATR
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coding for sample (ADHD/ASD) to the regression
models (to allow for possible differences in CNV
calling and/or ethnic differences between samples)
and applying these to the combined ADHD and
ASD data.
Secondary Analyses. To assess the extent to which
the observed overlap in enriched pathways is driven by
known loci for autism susceptibility, the enrichment
analysis was repeated on the complete pathway set,
omitting genes in 14 autism loci from previous studies
(Chr1 174.1–175.1 Mb, Chr2 13.12–13.16 Mb, Chr2 49.99
Mb–51.12 Mb, Chr3 2.11–3.08 Mb, Chr3 4.37–4.49 Mb,
Chr3 122.83–122.87 Mb, Chr3 174.59–175.49 Mb, Chr4
144.85 Mb, Chr6 161.68–163.07 Mb, Chr7 68.69–69.88
Mb, Chr10 87.33–88.12 Mb, Chr15 23.12–23.24 Mb,
Chr16 29.55–30.08 Mb, Chr22 49.44–49.52 Mb). Note
that these loci have previously been shown to overlap
with CNVs in a portion (n ¼ 366) of the current ADHD
sample.8
Moreover, it is possible that any observed overlap
in pathways enriched in both samples is due to the
physical overlap between case CNVs from the 2
samples, rather than shared biology per se (although
larger than expected physical overlap may, of course,
be due to shared biology). We tested whether ASD
participants’ CNVs are more likely than their control
peers’ CNVs to overlap participants with ADHD
participants’ CNVs, and vice versa, by ﬁtting the
following logistic regression model to the CNVs from
each sample: Overlap (y/n) w participants with ADHD
or ASD/control þ CNV length. A CNV was deﬁned as
overlapping if any part of that CNV overlapped any
case CNV from the other sample. A signiﬁcant posi-
tive regression coefﬁcient for the case/control term
is taken as evidence that case CNVs in 1 sample are
more likely than their corresponding control CNVs
to overlap case CNVs in the other sample, allowing
for CNV size (large CNVs being more likely to over-
lap than small ones). This analysis was initially carried
out genome-wide, using all CNVs, and then repeated
omitting CNVs in the autism regions listed above
to see if these regions accounted for any signiﬁcant
overlap.
The pathway enrichment analyses were repeated on
the complete pathway set after removing from both
sets of cases any CNV occurring in a participant with
ADHD that overlapped a CNV in the ASD sample
(leaving 102 ASD CNVs and 55 ADHD CNVs). A sig-
niﬁcant excess of pathways enriched in both samples
would provide evidence of shared biology even among
CNVs that do not hit the same genes.
To determine whether any observed overlaps in
signiﬁcant pathways were driven primarily by de-
letions or duplications, the pathway enrichment ana-
lyses were repeated on the complete pathway set, using
deletions or duplications alone.Y
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Signiﬁcant Overlap in Biological Pathways
Enriched in Both Samples
Table 1 shows the number of pathways achieving
differing signiﬁcance levels (p < .05, p < .01,
p < .001) in the ASD sample that were also sig-
niﬁcant at the same signiﬁcance level in the
ADHD sample. It can be seen that a signiﬁcant
overlap in enriched pathways for ASD and
ADHD is observed for both ASD de novo and
inherited CNVs, with the most signiﬁcant overlap
being observed in the analysis of all ASD CNVs
together.Enriched Pathways and Genes in the Combined
ADHD and ASD Dataset
Of the 100 pathways that were signiﬁcantly
(p < .05) enriched for case CNV hits in both the
ADHD and ASD samples, the 20 pathways that
were most signiﬁcantly enriched in the combined
ADHD and ASD (all CNV) samples are shown in
Table 2, together with the number of gene hits by
case CNVs, and the genes that are individually
signiﬁcantly (nominal p < .05) enriched for case
CNV hits in the combined ADHD and ASD
sample. Note that 3 of these pathways (nicotinic
acetylcholine receptor signaling, cell division, and
response to drug) have enrichment p values in the
combined ADHD and ASD data that are signiﬁ-
cant even after Bonferroni correction for 10,240
pathways tested (p < 4.88  106). This correction
is conservative, as the tested pathways are not
independent because of shared genes. The genes
hit by case CNVs in these 3 pathways are listed in
Table S1 (available online).Signiﬁcant Overlap in Physical Locations of Case
CNVs Between ASD and ADHD
ASD case CNVs were signiﬁcantly more likely
than ASD control CNVs to overlap with ADHDTABLE 1 Number of Pathways Achieving Given Levels of Enr
Autism Spectrum Disorder (ASD) Dataset That Were Also Sign
Attention-Deficit/Hyperactivity Disorder (ADHD) Sample
CNV Type (ASD)
p < .05
No. of Pathways p No.
De novo 58 .006
Inherited 72 .001
All 100 <.001
Note: p Values are given for the test of whether the number of enriched pathw
variant; de novo ¼ confirmed not to have been transmitted from either pare
JOURN
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speciﬁc ASD susceptibility loci were excluded
(p ¼ 8.28  103). Similarly, ADHD case CNVs
were signiﬁcantlymore likely to overlap with ASD
case CNVs than ADHD control CNVs (p ¼ 5.49 
104; known regions excluded: p ¼ 3.52  104).
Removal of CNVs in Known ASD Regions and
Overlapping Case CNVs
Secondary analyses assessed whether these
observed results were driven by speciﬁc loci
previously implicated in ASD and shown to
overlap with CNVs in a subsample of the current
ADHD sample,8 or by overlapping CNV regions
in the 2 groups, including CNVs other than those
falling within these known loci. Analyses were
repeated omitting these regions. Results are
shown in Table 3.
For the analysis omitting the speciﬁc regions, it
can be seen that the overlap in pathways is still
signiﬁcant, although, not surprisingly, the level of
signiﬁcance is reduced, particularly for analyses
based on the ASD de novo CNVs. For the anal-
ysis omitting all overlapping case CNVs, results
show a modestly signiﬁcant overlap of enriched
pathways in the ASD de novo CNVs but not in
the inherited CNVs or the total CNV set.
Pathway enrichment p values in the absence of
CNVs overlapping known ASD loci or over-
lapping a case CNV from the other disorder are
shown in Table S2 (available online) for all 100
pathways signiﬁcantly (p < .05) enriched in both
ADHD and ASD when all CNVs were analyzed
(primary analysis). Removing the known ASD
regions makes little difference to the pathway
enrichment, whereas removing case CNVs that
physically overlap with case CNVs from the other
disorder generally reduces enrichment signiﬁ-
cance considerably. Thus, most of the overlap in
enriched pathways can be attributed to case
CNVs in the disorders hitting the same loci (andichment Significance (p < .05, p < .01, p < .001) in the
ificantly Enriched at the Same Significance Level in the
p < .01 p < .001
of Pathways p No. of Pathways p
9 .016 1 .021
16 .004 1 .019
20 .001 1 .017
ays is greater than would be expected by chance. CNV ¼ copy number
nt.
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TABLE 2 The 20 Pathways (Ranked by Combined Attention-Deficit/Hyperactivity Disorder [ADHD] and Autism Spectrum Disorder [ASD] p Values) That Were Most














PAN-PW44 89 32 19 13 1.75E-07 3.39E-07 5.81E-03 Nicotinic acetylcholine receptor
signaling pathway
CHRNA7, MYH11
GO:51301 364 39 20 19 7.69E-07 2.19E-04 1.64E-03 Cell division AATF, NDE1, CHMP1B
GO:42493 322 50 28 22 8.94E-07 4.11E-04 5.69E-04 Response to drug ACACA, ABCC6,ABCC1
GO:5516 147 21 10 11 5.66E-06 2.87E-03 9.50E-04 Calmodulin binding MYH11
GO:5794 1,022 97 46 51 9.77E-06 2.10E-03 2.35E-03 Golgi apparatus ABCC1, TJP1, SYNRG, PARM1,
AATF, XYLT1, MPPE1
MGI:5620 212 23 15 8 1.15E-05 7.41E-04 1.82E-02 Abnormal muscle contractility MYH11
GO:6195 625 60 31 29 1.80E-05 6.26E-03 2.20E-03 Purine nucleotide catabolic process ABCC6, GNAL, ABCC1, DDX52
GO:9154 602 60 31 29 1.80E-05 6.26E-03 2.20E-03 Purine ribonucleotide catabolic
process
ABCC6, GNAL, ABCC1, DDX52
GO:9261 604 60 31 29 1.80E-05 6.26E-03 2.20E-03 Ribonucleotide catabolic process ABCC6, GNAL, ABCC1, DDX52
GO:9143 600 58 32 26 1.99E-05 3.75E-03 4.24E-03 Nucleoside triphosphate catabolic
process
ABCC6, GNAL, ABCC1, DDX52
GO:9166 642 62 32 30 2.21E-05 9.48E-03 2.18E-03 Nucleotide catabolic process ABCC6, GNAL, ABCC1, DDX52
GO:9141 640 64 33 31 2.48E-05 2.17E-02 9.13E-04 Nucleoside triphosphate metabolic
process
ABCC6, GNAL, ABCC1, DDX52
GO:9144 631 63 32 31 2.50E-05 2.18E-02 9.13E-04 Purine nucleoside triphosphate
metabolic process
ABCC6, GNAL, ABCC1, DDX52
GO:9199 628 63 32 31 2.50E-05 2.18E-02 9.13E-04 Ribonucleoside triphosphate
metabolic process
ABCC6, GNAL, ABCC1, DDX52
GO:9205 627 63 32 31 2.50E-05 2.18E-02 9.13E-04 Purine ribonucleoside triphosphate
metabolic process
ABCC6, GNAL, ABCC1, DDX52
PAN-PW16 69 18 10 8 2.76E-05 1.59E-04 2.56E-02 Cytoskeletal regulation by rho
GTPase
MYH11
GO:6633 108 23 11 12 2.77E-05 2.16E-03 4.19E-03 Fatty acid biosynthetic process ACACA,ABCC1
GO:48285 306 33 15 18 2.88E-05 1.59E-02 9.87E-04 organelle ﬁssion NDE1
GO:10927 94 29 18 11 2.88E-05 3.29E-03 2.48E-03 Cellular component assembly
involved in morphogenesis
MYH11, FOPNL
GO:6461 499 50 25 25 3.01E-05 8.82E-03 1.41E-03 Protein complex assembly ACACA, MYH11
Note: Pathways are sorted in order of enrichment p value in ADHD and ASD combined (the p (Combined) Column). Bonferroni correction for 10,240 pathways corresponds to a p (Combined) < 4.88  106. The number














































































TABLE 3 Number of Pathways Achieving Given Levels of Enrichment Significance (p < .05, p < .01, p < .001) in the
Autism Spectrum Disorder (ASD) Dataset That Were Also Significantly Enriched at the Same Significance Level in the
Attention-Deficit/Hyperactivity Disorder (ADHD) Sample
CNV Type (ASD)
p <.05 p < .01 p < .001
No. of Pathways p No. of Pathways p No. of Pathways p
Excluding “known” ASD regions
De novo 52 .006 4 .073 0 1
Inherited 78 .003 16 .004 1 .018
All 98 <.001 23 .001 2 .008
Excluding all overlapping CNVs
De novo 12 .009 3 .010 0 1
Inherited 4 .256 0 1 0 1
All 7 .130 1 .116 0 1
Note: p Values are given for the test of whether the number of enriched pathways is greater than would be expected by chance. Analyses exclude genes in
14 “known” autism regions, and any ASD case copy number variants (CNVs) that overlap ADHD case CNVs and vice versa (see text). De novo ¼
confirmed not to be transmitted from either parent.
MARTIN et al.thus genes) but not necessarily in regions previ-
ously implicated in ASD.
Analysis of Deletions and Duplications Separately
Of the 85 case CNVs in the ADHD sample, 21
were deletions and 64 were duplications. Among
the 78 control CNVs in the ADHD dataset, 13
were deletions and 65 were duplications. Of the
133 case CNVs in the ASD dataset, 34 were de-
letions and 99 were duplications. Among the
control CNVs in the ASD dataset, 65 were de-
letions and 150 were duplications. The numbers of
pathways signiﬁcantly enriched in both ADHD
and ASD are provided in Table 4. Analyzing du-
plications and deletions separately reduces both
the number of pathways signiﬁcantly enriched in
both ADHD and ASD and the signiﬁcance of any
excess. There was no evidence that either de-
letions or duplications separately account for the
observed pathway overlap between ADHD and
ASD. Pathway-speciﬁc enrichment p values for
the 100 pathways signiﬁcantly enriched (p < .05)
in both ADHD and ASD when deletions and
duplications are analyzed separately are shown in
Table S3 (available online).
List of CNVs Used in the Analyses
A complete list of the case CNVs >500 kb (ADHD
and ASD) used in the analyses is given in
Table S4 (available online).
DISCUSSION
The results show that the biological pathways
enriched (p < .05) for CNVs in the ADHD sample
(relative to controls) as a group show moreJOURN
766 www.jaacap.orgenrichment for CNVs in the ASD sample (relative
to an independent set of controls) than expected
by chance. A similar enrichment was observed
(results not shown) when the analyses were per-
formed in the reverse direction (i.e., the pathways
enriched in the ASD sample tested in the ADHD
sample). This ﬁnding indicates the presence of
common biological liability for ADHD and ASD.
Signiﬁcant overlap was observed for both de
novo and inherited CNVs in the ASD sample,
although these results are not independent
because the same control CNVs were used.
Given that an earlier study using part of the
current ADHD sample found enrichment in
ADHD CNV loci that had been previously
implicated in ASD,8 those loci were omitted from
the current analysis to obtain independent repli-
cation of the earlier ﬁnding that ASD CNV loci
were also found in children with ADHD. The
continued signiﬁcant overlap of CNVs and
pathways suggests that other CNV loci are also
contributing to this effect, although, given the
small number of loci in this additional analysis,
the signiﬁcance of overlap with ADHD and de
novo ASD CNVs is reduced. Moreover, omitting
all ADHD case CNVs overlapping at all with
ASD case CNVs and vice versa from the analyses
also shows more generally that shared biological
pathways are implicated in ADHD and ASD
above and beyond overlap of speciﬁc CNV re-
gions. Given that performing this strict analysis
with no physically overlapping CNVs substan-
tially reduces the pool of CNVs in the analysis, it
is remarkable that there is still demonstrable
overlap in biological pathways tapped into by
CNVs from participants with ADHD and ASD.AL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
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TABLE 4 Number of Pathways Achieving Given Levels of Enrichment Significance (p < .05, p < .01, p < .001) in the
Autism Spectrum Disorder (ASD) Dataset That Were Also Nominally Significantly Enriched at the Same Significance Level
in the Attention-Deficit/Hyperactivity Disorder (ADHD) Sample
CNV Type (ASD)
p < .05 p < .01 p < .001
No. of Pathways p No. of Pathways p No. of Pathways p
All 100 <.001 20 .001 1 .017
Deletions 1 .153 0 1 0 1
Duplications 41 .032 2 .203 0 1
Note: p Values are given for the test of whether the number of enriched pathways is greater than would be expected by chance. Analyses are shown for all
copy number variants (CNVs) and also for deletions and duplications separately.
BIOLOGICAL OVERLAP OF ADHD AND ASDTo highlight which speciﬁc pathways contain
enrichment evidence in both ADHD and ASD,
the 2 samples were combined in a joint analysis.
Three pathways showed signiﬁcant enrichment
after correction for multiple testing (“nicotinic
acetylcholine receptor signalling pathway,” “cell
division,” and “response to drug”). Owing to the
deﬁnition of pathway categories, many of the
analyzed pathways overlap with one another,
including pathways embedded in one another.
The 3 signiﬁcant pathways contain different
signiﬁcant genes (Table 2 and Table S1; the latter
is available online) despite each pathway con-
taining at least 1 signiﬁcant gene from the same
region on chromosome 16 (MYH11, NDE1,
ABCC1, ABCC6), and a signiﬁcant (or nearly
signiﬁcant) gene from the same region on chro-
mosome 17 (MYO19, AATF, ACACA). It is
unclear which gene(s) in these regions is res-
ponsible for the CNV enrichment. It should be
noted that even when these regions are removed
from the analysis, all 3 pathways still show sig-
niﬁcant enrichment (nicotinic acetylcholine re-
ceptor signaling pathway: p ¼ 1.17  103, cell
division: p ¼ 6.06  103, response to drug:
p ¼ 3.41  103).
It is interesting to note that the neurobiology
encompassed by these pathways enriched in
both ADHD and ASD has been implicated in a
previous pathway analysis of the current ADHD
sample, which explored the overlap of common
(SNPs) and rare (CNVs) variants.16 The most
signiﬁcantly enriched pathway in the combined
ADHD and ASD samples (Table 2) is the
PANTHER pathway “nicotinic acetylcholine
receptor signalling,” which is also signiﬁcantly
enriched in both ADHD and ASD separately.
This pathway contains 2 genes, MYH11 and
CHRNA7, of potential interest. The gene CHRNA7
encodes the alpha 7 nicotinic acetylcholine re-
ceptor, which has a role in calcium signaling inJOURNAL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATR
VOLUME 53 NUMBER 7 JULY 2014the brain. This gene was previously shown to be
enriched for both CNV hits and GWAS signal in
the current ADHD sample.16 It has been found
also to have duplications spanning it in a
genome-wide analysis of CNVs, a ﬁnding that
was replicated in independent ADHD samples.10
CHRNA7 is located at the chromosomal locus of
15q13.3, and deletions at this locus have been
found to be associated with different neuro-
developmental abnormalities and neuropsychi-
atric disorders.29 There is evidence from a small
case series that deletions and duplications at this
locus could also be associated with features of
ASD.30 MYH11 is at the chromosomal locus of
16p13.1, a region that has previously been
shown to be enriched for CNVs in a subsample of
participants with ADHD, at a genome-wide level
relative to controls.8 This region has also been
implicated in autism,31 schizophrenia,32 and in-
tellectual disability/multiple congenital anoma-
lies.33 It should be noted that MYH11 is involved
in numerous other enriched pathways, suggest-
ing that it may inﬂuence ADHD and ASD sus-
ceptibility through multiple biological processes.
Interestingly, the current analysis has not
implicated the types of biological pathways pre-
viously reported in pathway analyses in ASD
samples that are related to synaptic and neuronal
plasticity and those involved in neurotransmis-
sion or synapse formation and maintenance.34,35
This is likely because such pathways are not
signiﬁcantly enriched for case CNV hits in the
ADHD sample.
Given the very high level of comorbidity and
symptom correlation between ADHD and ASD,1
it is arguable as to whether it is clinically mean-
ingful to attempt to distinguish “pure” ASD or
ADHD cases. Although children with a clinician’s
diagnosis of ASD were excluded from the ADHD
sample, previous clinical analyses have reported
subthreshold ASD traits in this sample.36Y
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symptoms were not available for the ASD cases
for this analysis.18 Thus, it is possible that the
overlap in biological pathways detected in this
study may be reﬂecting the presence of sub-
threshold ADHD and ASD traits in the samples.
However, given the strong relationship of the 2
conditions, the value of attempting to control for
subthreshold traits is unclear. Also, despite
overlaps, ADHD and ASD are clinically distinc-
tive. Furthermore, disruption of synaptic func-
tion by rare CNVs may play a more important
role in some neurodevelopmental processes,
such as those involved in ASD and ID, but not
all. Thus far, synaptic functions have not been
implicated by pathway analysis of SNP data in
ADHD.16
Although the participants with ADHD and
the WTCCC2 controls were genotyped on
different chips, CNV calling used only the SNPs
common to both genotyping chips, with the
same QC procedures used to ﬁlter the SNPs.
Thus, the CNV calls are comparable between
participants with ADHD or ASD and controls,
particularly for large (>500-kb) CNVs that are
called with high accuracy and reliability. The
participants with ASD and controls were geno-
typed on the same chips, using the same QC
protocols, so again the CNV calls are directly
comparable between participants with ASD and
controls. The participants with ADHD and
WTCCC controls are of similar ethnic back-
grounds (UK individuals of white ethnicity), as
are the participants with ASD and controls (US
white individuals). Note that, in the combined
analysis, differences in ethnicity and CNV calling
between the ADHD and ASD samples are con-
trolled by including “sample” as a covariate.
Thus, signiﬁcant pathway enrichments are un-
likely to have arisen because of population
stratiﬁcation or differences in CNV calling.
One limitation of this study is that the bio-
logical pathway categories were deﬁned based on
the GO, KEGG, PANTHER, MGI, and MSigDB
databases, which depend on the accuracy of the
annotations in these databases. As the contents of
these databases come to reﬂect the growing
knowledge of these processes, pathway analyses
such as those described in this article will be
better able to implicate speciﬁc biological pro-
cesses in disease etiology. Furthermore, future
studies need to assess the functional effects of
genes implicated in speciﬁc overlapping path-
ways, to determine the exact nature and extentJOURN
768 www.jaacap.orgof the shared underlying biology of ADHD
and ASD.
It is of note that the overlap in pathways was
detected for de novo as well as inherited CNVs.
Both inherited and de novo CNVs are enriched in
participants with ASD relative to controls, with a
higher frequency of de novo CNVs in females
than in males and in sporadic ASD cases (i.e.,
families with a single affected child) than in
“multiplex” families (i.e., with more than 1
affected child).37-40 De novo CNVs have also been
reported in individuals with ADHD, although at
a lower rate than that reported in ASD and
schizophrenia.9 Unfortunately, because of the
unavailability of complete parental genetic data,
it is not known whether the CNVs in the ADHD
sample were inherited or de novo.
Although the majority of the CNVs in this
sample (both in participants with ADHD or ASD
and in controls) were duplications, the strength of
the signal was reduced by analyzing deletions
and duplications separately. This suggests that
both types of CNVs likely contribute to disrupt-
ing biological processes underlying ADHD
and ASD.
There is evidence that large, rare CNVs are
more likely to occur in children with ADHD who
have comorbid ID (IQ <70).8 Similarly, there is a
somewhat greater rate of CNVs in children with
ASD with ID relative to those without ID.41
Although children with ID were excluded from
the ADHD analyses, the ASD sample did not
make such exclusions. However, this would
serve to reduce biological overlap, and it means
that the results cannot be explained by comor-
bid ID.
In conclusion, this study provides evidence
that ADHD and ASD show signiﬁcant overlap of
shared biological processes being disrupted by
CNVs. This ﬁnding gives preliminary evidence of
the mechanisms that may underpin observed
phenotypic overlap1 and shared heritability.4 The
ﬁndings would beneﬁt from replication and
further investigation using larger collaborative
samples and future updated versions of pathway
annotation databases to determine the speciﬁc
biological pathways that are being affected by
these rare variants. These ﬁndings further
strengthen the conceptual grouping of ADHD
and ASD as related neurodevelopmental disor-
ders. Further research in this area has the poten-
tial to shed light on heterogeneity of ADHD and
ASD clinical phenotypes and the subtyping of
child neurodevelopmental disorders. &AL OF THE AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY
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TABLE S1 Genes in the 3 Pathways Significantly Enriched in the Combined Attention-Deficit/Hyperactivity Disorder
(ADHD) and Autism Spectrum Disorder (ASD) Dataset, After Multiple Testing
Pathway Entrez ID Gene Symbol Chr Start End
No. of Hits
(Combined Cases) p (Combined)
GO:42493 4363 ABCC1 16 15950935 16144432 11 2.22E-05
GO:51301 54820 NDE1 16 15651605 15726491 11 2.22E-05
PAN-PW44 4629 MYH11 16 15704493 15858388 11 2.22E-05
GO:42493 368 ABCC6 16 16150923 16224838 11 3.66E-04
PAN-PW44 1139 CHRNA7 15 30110018 30248541 11 1.35E-02
GO:51301 57132 CHMP1B 18 11841426 11842697 2 2.27E-02
GO:51301 26574 AATF 17 32380288 32488284 3 2.82E-02
GO:42493 31 ACACA 17 32516040 32841015 3 2.82E-02
PAN-PW44 80179 MYO19 17 31925712 31964838 2 6.11E-02
GO:51301 4851 NOTCH1 9 138508717 138560059 2 6.90E-02
GO:51301 84861 KLHL22 22 19125806 19180122 4 7.53E-02
PAN-PW44 9342 SNAP29 22 19543292 19574109 4 7.53E-02
GO:42493 9420 CYP7B1 8 65671246 65873902 1 7.75E-02
GO:51301 1070 CETN3 5 89725284 89741359 1 7.75E-02
GO:42493 7436 VLDLR 9 2611793 2644485 1 7.79E-02
GO:51301 25909 AHCTF1 1 245069023 245148302 1 7.85E-02
GO:42493 2571 GAD1 2 171381446 171425907 1 8.08E-02
GO:42493 65985 AACS 12 124115878 124193824 1 8.40E-02
GO:51301 389 RHOC 1 113045272 113051548 1 8.45E-02
GO:42493 389 RHOC 1 113045272 113051548 1 8.45E-02
GO:42493 58189 WFDC1 16 82885902 82920951 1 8.54E-02
GO:42493 5174 PDZK1 1 144439083 144475430 1 9.41E-02
GO:42493 11280 SCN11A 3 38862264 38967056 1 9.49E-02
GO:51301 29945 ANAPC4 4 24987946 25029218 1 1.19E-01
GO:42493 9429 ABCG2 4 89230440 89299035 1 1.27E-01
PAN-PW44 71 ACTG1 17 77091594 77094422 1 1.28E-01
GO:51301 51529 ANAPC11 17 77442895 77451655 1 1.28E-01
GO:42493 1374 CPT1A 11 68278664 68365881 1 1.28E-01
GO:42493 51083 GAL 11 68208559 68215219 1 1.28E-01
GO:51301 151011 SEPT-10 2 109657665 109729072 1 1.29E-01
GO:51301 10015 PDCD6IP 3 33814561 33886198 1 1.30E-01
GO:51301 23122 CLASP2 3 33512741 33734852 1 1.30E-01
GO:51301 23310 NCAPD3 11 133527547 133599636 1 1.31E-01
GO:51301 85444 LRRCC1 8 86206629 86245567 1 1.33E-01
PAN-PW44 1103 CHAT 10 50487147 50543156 1 1.43E-01
PAN-PW44 6572 SLC18A3 10 50488353 50490772 1 1.43E-01
GO:42493 1103 CHAT 10 50487147 50543156 1 1.43E-01
GO:42493 2567 GABRG3 15 24799263 25451729 2 1.46E-01
GO:42493 64170 CARD9 9 138378229 138387939 1 1.59E-01
GO:51301 1731 SEPT-1 16 30296957 30301672 1 1.80E-01
GO:42493 6609 SMPD1 11 6368231 6372802 1 1.86E-01
GO:42493 1019 CDK4 12 56428270 56432431 1 1.91E-01
GO:51301 1017 CDK2 12 54646826 54652835 1 1.91E-01
GO:51301 1019 CDK4 12 56428270 56432431 1 1.91E-01
PAN-PW44 4640 MYO1A 12 55708568 55730160 1 1.91E-01
GO:42493 2065 ERBB3 12 54760159 54783395 1 1.91E-01
GO:42493 9501 RPH3AL 17 62293 202576 1 1.95E-01
GO:42493 9961 MVP 16 29731591 29766842 5 2.82E-01
GO:51301 29882 ANAPC2 9 139189057 139202878 2 3.95E-01
GO:51301 93426 SYCE1 10 135217395 135232866 1 4.36E-01
GO:42493 1312 COMT 22 18309309 18336530 1 6.33E-01
GO:51301 5413 SEPT-5 22 18081987 18092297 1 6.33E-01
Note: For each gene, the number of case copy number variants hitting that gene is given (if greater than zero), together with gene-specific enrichment p-value.
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TABLE S2 Pathway-Specific Enrichment p Values in Attention-Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD) Samples for the 100 Pathways
Significantly Enriched (p < .05) in Both ADHD and ASD
Pathway ID
No. of
Genes p (Combined) p (ADHD)
p (ADHD No
ASD loci)
p (ADHD No Case
CNV Overlap) p (ASD)
p (ASD No
ASD Loci)
p (ASD No Case
CNV Overlap) Pathway Description
PAN-PW44 89 1.75E-07 3.39E-07 3.06E-07 1.78E-02 5.81E-03 4.70E-03 2.85E-01 Nicotinic acetylcholines receptor signaling pathway
GO:51301 364 7.69E-07 2.19E-04 3.41E-04 1.48E-02 1.64E-03 8.20E-04 4.13E-03 Cell division
GO:42493 322 8.94E-07 4.11E-04 1.67E-04 2.10E-02 5.69E-04 6.92E-04 6.91E-03 Response to drug
GO:5516 147 5.66E-06 2.87E-03 2.51E-03 2.86E-01 9.50E-04 5.97E-04 7.20E-04 Calmodulin binding
GO:5794 1022 9.77E-06 2.10E-03 1.34E-03 7.62E-03 2.35E-03 3.68E-03 3.55E-02 Golgi apparatus
MGI:5620 212 1.15E-05 7.41E-04 6.43E-04 2.14E-02 1.82E-02 1.71E-02 1.00E-01 Abnormal muscle contractility
GO:6195 625 1.80E-05 6.26E-03 5.13E-03 1.28E-01 2.20E-03 1.32E-03 1.46E-03 Purine nucleotide catabolic process
GO:9154 602 1.80E-05 6.26E-03 5.13E-03 1.28E-01 2.20E-03 1.32E-03 1.46E-03 Purine ribonucleotide catabolic process
GO:9261 604 1.80E-05 6.26E-03 5.13E-03 1.28E-01 2.20E-03 1.32E-03 1.46E-03 Ribonucleotide catabolic process
GO:9143 600 1.99E-05 3.75E-03 5.13E-03 1.28E-01 4.24E-03 2.65E-03 3.33E-03 Nucleoside triphosphate catabolic process
GO:9166 642 2.21E-05 9.48E-03 1.24E-02 2.12E-01 2.18E-03 1.31E-03 1.45E-03 Nucleotide catabolic process
GO:9141 640 2.48E-05 2.17E-02 1.26E-02 3.01E-01 9.13E-04 1.35E-03 5.22E-03 Nucleoside triphosphate metabolic process
GO:9144 631 2.50E-05 2.18E-02 1.26E-02 3.01E-01 9.13E-04 1.35E-03 5.22E-03 Purine nucleoside triphosphate metabolic process
GO:9199 628 2.50E-05 2.18E-02 1.26E-02 3.01E-01 9.13E-04 1.35E-03 5.22E-03 Ribonucleoside triphosphate metabolic process
GO:9205 627 2.50E-05 2.18E-02 1.26E-02 3.01E-01 9.13E-04 1.35E-03 5.22E-03 Purine ribonucleoside triphosphate metabolic process
PAN-PW16 69 2.76E-05 1.59E-04 1.45E-04 3.99E-02 2.56E-02 1.81E-02 6.47E-02 Cytoskeletal regulation by Rho GTPase
GO:6633 108 2.77E-05 2.16E-03 2.03E-03 1.52E-01 4.19E-03 2.20E-03 1.25E-03 Fatty acid biosynthetic process
GO:10927 94 2.88E-05 3.29E-03 3.05E-03 2.80E-01 2.48E-03 2.49E-03 8.79E-03 Cellular component assembly involved in morphogenesis
GO:48285 306 2.88E-05 1.59E-02 8.26E-03 3.56E-01 9.87E-04 1.17E-03 3.94E-03 Organelle ﬁssion
GO:6461 499 3.01E-05 8.82E-03 9.44E-03 8.83E-02 1.41E-03 1.98E-03 1.68E-02 Protein complex assembly
GO:70271 503 3.01E-05 8.82E-03 9.44E-03 8.83E-02 1.41E-03 1.98E-03 1.68E-02 Protein complex biogenesis
GO:9146 597 3.40E-05 6.26E-03 5.13E-03 1.28E-01 4.24E-03 2.65E-03 3.33E-03 Purine nucleoside triphosphate catabolic process
GO:9203 596 3.40E-05 6.26E-03 5.13E-03 1.28E-01 4.24E-03 2.65E-03 3.33E-03 Ribonucleoside triphosphate catabolic process
GO:9207 596 3.40E-05 6.26E-03 5.13E-03 1.28E-01 4.24E-03 2.65E-03 3.33E-03 Purine ribonucleoside triphosphate catabolic process
GO:16887 362 3.70E-05 9.25E-04 7.28E-04 2.76E-02 2.59E-02 2.35E-02 1.10E-01 ATPase activity
GO:6200 365 3.70E-05 9.25E-04 7.28E-04 2.76E-02 2.59E-02 2.35E-02 1.10E-01 ATP catabolic process
GO:280 293 4.29E-05 5.63E-03 2.31E-03 2.29E-01 4.54E-03 5.86E-03 2.45E-02 Nuclear division
GO:7067 293 4.29E-05 5.63E-03 2.31E-03 2.29E-01 4.54E-03 5.86E-03 2.45E-02 Mitosis
GO:51649 1114 4.91E-05 4.32E-04 4.62E-04 1.76E-03 3.23E-02 4.90E-02 2.68E-01 Establishment of localization in cell
GO:87 301 5.39E-05 1.50E-02 7.86E-03 3.37E-01 2.02E-03 2.50E-03 9.79E-03 M phase of mitotic cell cycle
GO:34655 667 5.55E-05 4.13E-02 5.14E-02 4.00E-01 1.14E-03 6.48E-04 6.08E-04 Nucleobase-containing compound catabolic process
GO:44270 693 5.55E-05 4.13E-02 5.14E-02 4.00E-01 1.14E-03 6.48E-04 6.08E-04 Cellular nitrogen compound catabolic process
GO:6936 171 5.55E-05 3.88E-03 1.18E-03 5.00E-01 5.93E-03 7.17E-03 3.58E-01 Muscle contraction
MGI:4811 331 6.15E-05 1.09E-04 9.37E-05 6.39E-02 3.97E-02 3.21E-02 1.94E-01 Abnormal neuron physiology
MGI:1876 190 6.18E-05 2.29E-02 2.15E-02 2.46E-01 2.09E-03 1.34E-03 3.51E-03 Decreased inﬂammatory response


































































Genes p (Combined) p (ADHD)
p (ADHD No
ASD loci)
p (ADHD No Case
CNV Overlap) p (ASD)
p (ASD No
ASD Loci)
p (ASD No Case
CNV Overlap) Pathway Description
GO:72523 631 8.36E-05 3.13E-02 2.70E-02 2.87E-01 2.20E-03 1.32E-03 1.46E-03 Purine-containing compound catabolic process
GO:51656 96 9.17E-05 1.97E-04 4.11E-04 9.02E-02 3.09E-02 2.73E-02 3.83E-01 Establishment of organelle localization
MGI:1756 97 9.69E-05 2.54E-02 2.41E-02 2.75E-01 1.29E-03 1.06E-03 3.93E-03 Abnormal urination
MGI:5278 224 1.01E-04 4.60E-04 4.16E-04 3.21E-02 2.15E-02 2.07E-02 6.82E-02 Abnormal cholesterol homeostasis
GO:16053 234 1.06E-04 3.82E-03 5.86E-03 2.05E-01 1.14E-02 7.04E-03 4.91E-03 Organic acid biosynthetic process
GO:46394 234 1.06E-04 3.82E-03 5.86E-03 2.05E-01 1.14E-02 7.04E-03 4.91E-03 Carboxylic acid biosynthetic process
GO:33559 70 1.15E-04 4.80E-02 4.66E-02 1.24E-02 4.98E-04 2.43E-04 1.35E-04 Unsaturated fatty acid metabolic process
GO:6690 67 1.15E-04 4.80E-02 4.66E-02 1.24E-02 4.98E-04 2.43E-04 1.35E-04 Icosanoid metabolic process
MGI:5294 368 1.15E-04 1.58E-03 1.40E-03 1.50E-01 1.62E-02 1.20E-02 1.14E-01 Abnormal heart ventricle morphology
GO:51641 1302 1.24E-04 1.47E-03 1.65E-03 3.27E-03 3.40E-02 5.11E-02 3.10E-01 Cellular localization
MGI:180 197 1.55E-04 8.00E-04 7.44E-04 5.62E-02 2.11E-02 2.05E-02 8.24E-02 Abnormal circulating cholesterol level
GO:42623 285 1.56E-04 1.87E-03 1.56E-03 5.06E-02 4.77E-02 4.38E-02 2.00E-01 ATPase activity, coupled
GO:279 434 1.95E-04 4.00E-02 2.61E-02 3.92E-01 2.50E-03 3.39E-03 7.70E-03 M phase
GO:6692 30 2.23E-04 4.82E-02 4.68E-02 1.22E-02 1.15E-03 6.55E-04 6.97E-04 Prostanoid metabolic process
GO:46034 385 2.27E-04 1.50E-02 7.89E-03 2.14E-01 1.36E-02 2.10E-02 1.81E-01 ATP metabolic process
MGI:1663 388 2.70E-04 1.31E-02 1.20E-02 9.09E-02 2.03E-02 1.71E-02 3.13E-02 Abnormal digestive system physiology
GO:793 145 2.79E-04 2.41E-03 2.27E-03 1.86E-01 2.62E-02 2.41E-02 6.59E-02 Condensed chromosome
KEGG4020 177 2.94E-04 2.23E-02 2.11E-02 1.26E-01 5.10E-03 3.55E-03 5.72E-02 Calcium signaling pathway
GO:19752 694 3.00E-04 1.51E-02 2.00E-02 1.23E-01 8.88E-03 5.46E-03 6.48E-03 Carboxylic acid metabolic process
GO:42180 709 3.00E-04 1.51E-02 2.00E-02 1.23E-01 8.88E-03 5.46E-03 6.48E-03 Cellular ketone metabolic process
GO:43436 694 3.00E-04 1.51E-02 2.00E-02 1.23E-01 8.88E-03 5.46E-03 6.48E-03 Oxoacid metabolic process
GO:6082 712 3.07E-04 9.49E-03 1.26E-02 7.52E-02 1.36E-02 8.70E-03 1.03E-02 Organic acid metabolic process
GO:43292 135 3.12E-04 3.91E-02 2.08E-02 2.00E-01 2.72E-03 5.56E-04 1.15E-01 Contractile ﬁber
GO:22857 935 3.45E-04 7.98E-03 5.42E-03 2.25E-01 2.04E-02 2.65E-02 2.66E-01 Transmembrane transporter activity
GO:775 149 3.81E-04 1.97E-03 5.41E-04 9.56E-02 4.10E-02 6.16E-02 3.30E-01 Chromosome, centromeric region
MGI:2462 185 3.85E-04 5.97E-03 8.63E-03 1.68E-01 3.62E-02 5.24E-02 2.56E-01 Abnormal granulocyte physiology
MGI:3947 216 4.01E-04 8.00E-04 7.44E-04 5.62E-02 4.11E-02 3.96E-02 1.33E-01 Abnormal cholesterol level
GO:7613 57 4.13E-04 2.69E-03 2.65E-03 4.74E-01 1.50E-02 1.53E-02 3.53E-01 Memory
GO:33036 1342 4.43E-04 1.75E-02 2.04E-02 9.05E-02 1.38E-02 1.96E-02 1.80E-01 Macromolecule localization
MGI:8873 166 4.48E-04 1.01E-02 8.96E-03 1.26E-01 4.39E-02 4.20E-02 1.40E-01 Increased physiological sensitivity to xenobiotic
GO:5929 195 4.71E-04 1.22E-03 1.09E-03 2.07E-01 4.82E-02 4.42E-02 8.52E-02 Cilium
GO:55074 208 5.40E-04 4.48E-03 4.22E-03 1.93E-02 4.84E-02 3.92E-02 1.81E-01 Calcium ion homeostasis
GO:72507 214 5.40E-04 4.48E-03 4.22E-03 1.93E-02 4.84E-02 3.92E-02 1.81E-01 Divalent inorganic cation homeostasis
MGI:2064 254 5.53E-04 1.06E-02 9.84E-03 4.37E-02 2.28E-02 1.85E-02 1.18E-01 Seizures
GO:44449 121 5.55E-04 3.91E-02 2.08E-02 2.00E-01 5.55E-03 1.30E-03 2.58E-01 Contractile ﬁber part
MGI:2106 553 6.50E-04 1.72E-02 1.50E-02 1.44E-01 2.86E-02 2.39E-02 4.78E-02 Abnormal muscle physiology


















































































Genes p (Combined) p (ADHD)
p (ADHD No
ASD loci)
p (ADHD No Case
CNV Overlap) p (ASD)
p (ASD No
ASD Loci)
p (ASD No Case
CNV Overlap) Pathway Description
GO:776 92 6.78E-04 3.18E-03 2.94E-04 4.48E-01 3.30E-02 4.71E-02 3.78E-01 Kinetochore
GO:8104 1100 6.95E-04 3.19E-02 3.69E-02 1.36E-01 1.28E-02 1.76E-02 1.97E-01 Protein localization
GO:43623 172 7.18E-04 4.36E-03 4.08E-03 3.86E-01 2.65E-02 2.11E-02 3.24E-02 Cellular protein complex assembly
GO:71822 596 7.36E-04 1.89E-02 2.09E-02 1.42E-01 1.34E-02 1.85E-02 5.77E-02 Protein complex subunit organization
GO:23061 114 7.63E-04 9.80E-03 7.22E-03 2.32E-03 4.05E-02 5.57E-02 7.95E-02 Signal release
GO:3001 114 7.63E-04 9.80E-03 7.22E-03 2.32E-03 4.05E-02 5.57E-02 7.95E-02 Generation of a signal involved in cell-cell signaling
GO:42470 93 7.94E-04 1.16E-02 1.10E-02 4.27E-01 3.39E-02 2.76E-02 2.33E-01 Melanosome
GO:48770 93 7.94E-04 1.16E-02 1.10E-02 4.27E-01 3.39E-02 2.76E-02 2.33E-01 Pigment granule
GO:5261 282 9.70E-04 2.03E-02 1.34E-02 1.22E-01 1.83E-02 2.69E-02 4.14E-01 Cation channel activity
GO:5694 574 1.12E-03 1.19E-02 7.49E-03 9.19E-02 4.24E-02 6.46E-02 2.88E-01 Chromosome
GO:48878 656 1.20E-03 2.04E-02 2.83E-02 1.61E-02 4.10E-02 3.15E-02 1.53E-01 Chemical homeostasis
GO:42803 484 1.21E-03 8.65E-03 1.18E-02 4.42E-02 4.66E-02 7.05E-02 4.01E-01 Protein homodimerization activity
GO:5215 1194 1.32E-03 2.76E-02 2.09E-02 3.49E-01 3.27E-02 4.32E-02 3.28E-01 Transporter activity
GO:7601 203 1.42E-03 2.04E-02 1.87E-02 2.18E-01 3.00E-02 2.71E-02 3.25E-01 Visual perception
GO:44283 334 2.00E-03 2.33E-02 1.35E-02 4.75E-01 3.33E-02 4.86E-02 8.27E-02 Small molecule biosynthetic process
GO:6631 240 2.10E-03 1.76E-02 1.67E-02 2.95E-01 3.61E-02 2.59E-02 1.75E-02 Fatty acid metabolic process
MGI:6042 414 2.22E-03 2.39E-02 3.39E-02 2.61E-01 3.13E-02 4.46E-02 2.18E-01 Increased apoptosis
GO:44085 1240 2.44E-03 1.42E-02 1.59E-02 6.05E-02 2.00E-02 2.94E-02 4.54E-02 Cellular component biogenesis
GO:32787 344 2.46E-03 1.76E-02 1.67E-02 2.95E-01 2.81E-02 2.07E-02 9.38E-03 Monocarboxylic acid metabolic process
GO:30030 681 2.84E-03 3.37E-02 2.31E-02 2.41E-01 4.19E-02 5.10E-02 1.12E-01 Cell projection organization
GO:42330 530 3.68E-03 4.22E-02 2.99E-02 4.18E-01 4.03E-02 4.99E-02 4.20E-01 Taxis
GO:6935 530 3.68E-03 4.22E-02 2.99E-02 4.18E-01 4.03E-02 4.99E-02 4.20E-01 Chemotaxis
GO:65003 713 3.69E-03 2.93E-02 3.32E-02 1.68E-01 2.23E-02 3.12E-02 4.01E-02 Macromolecular complex assembly
GO:43279 79 4.69E-03 2.31E-02 2.27E-02 4.33E-01 4.21E-02 4.07E-02 3.70E-01 Response to alkaloid
GO:22607 1107 5.06E-03 2.98E-02 3.36E-02 1.36E-01 2.29E-02 3.35E-02 5.65E-02 Cellular component assembly
MGI:3203 78 7.57E-03 4.01E-02 3.95E-02 4.17E-01 4.45E-02 4.16E-02 2.53E-01 Increased neuron apoptosis
MGI:1402 231 7.81E-03 2.22E-02 2.18E-02 3.97E-01 4.31E-02 3.33E-02 1.52E-01 Hypoactivity































































TABLE S3 Pathway-Specific Enrichment p Values in Attention-Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD) Samples for the 100 Pathways
Significantly Enriched (p < .05) in Both ADHD and ASD When Deletions and Duplications Are Analyzed Separately
Pathway p (Combined) p (ADHD) p (ADHD del) p (ADHD dup) p (ASD) p (ASD del) p (ASD dup) Function
PAN-PW44 1.75E-07 3.39E-07 3.84E-01 1.41E-07 5.81E-03 3.49E-03 6.72E-02 Nicotinic acetylcholine receptor signaling pathway
GO:51301 7.69E-07 2.19E-04 3.81E-01 7.30E-05 1.64E-03 2.54E-01 2.95E-03 Cell division
GO:42493 8.94E-07 4.11E-04 4.01E-01 1.18E-04 5.69E-04 8.78E-04 3.24E-02 Response to drug
GO:5516 5.66E-06 2.87E-03 N/A 2.87E-03 9.50E-04 7.33E-02 4.65E-03 Calmodulin binding
GO:5794 9.77E-06 2.10E-03 2.40E-01 1.15E-03 2.35E-03 1.02E-02 2.62E-02 Golgi apparatus
MGI:5620 1.15E-05 7.41E-04 2.24E-01 1.80E-03 1.82E-02 1.22E-01 3.64E-02 Abnormal muscle contractility
GO:6195 1.80E-05 6.26E-03 4.10E-02 5.83E-03 2.20E-03 1.68E-02 3.29E-02 Purine nucleotide catabolic process
GO:9154 1.80E-05 6.26E-03 4.10E-02 5.83E-03 2.20E-03 1.68E-02 3.29E-02 Purine ribonucleotide catabolic process
GO:9261 1.80E-05 6.26E-03 4.10E-02 5.83E-03 2.20E-03 1.68E-02 3.29E-02 Ribonucleotide catabolic process
GO:9143 1.99E-05 3.75E-03 4.08E-02 5.83E-03 4.24E-03 4.90E-02 3.30E-02 Nucleoside triphosphate catabolic process
GO:9166 2.21E-05 9.48E-03 4.08E-02 1.45E-02 2.18E-03 1.68E-02 3.29E-02 Nucleotide catabolic process
GO:9141 2.48E-05 2.17E-02 3.82E-01 1.41E-02 9.13E-04 3.63E-03 3.07E-02 Nucleoside triphosphate metabolic process
GO:9144 2.50E-05 2.18E-02 3.82E-01 1.41E-02 9.13E-04 3.63E-03 3.07E-02 Purine nucleoside triphosphate metabolic process
GO:9199 2.50E-05 2.18E-02 3.82E-01 1.41E-02 9.13E-04 3.63E-03 3.07E-02 Ribonucleoside triphosphate metabolic process
GO:9205 2.50E-05 2.18E-02 3.82E-01 1.41E-02 9.13E-04 3.63E-03 3.07E-02 Purine ribonucleoside triphosphate metabolic process
PAN-PW16 2.76E-05 1.59E-04 N/A 1.59E-04 2.56E-02 7.33E-02 9.99E-02 Cytoskeletal regulation by Rho GTPase
GO:6633 2.77E-05 2.16E-03 2.69E-01 1.58E-03 4.19E-03 7.33E-02 2.12E-02 Fatty acid biosynthetic process
GO:10927 2.88E-05 3.29E-03 4.81E-01 3.04E-03 2.48E-03 4.87E-02 1.60E-02 Cellular component assembly involved in morphogenesis
GO:48285 2.88E-05 1.59E-02 2.06E-01 1.96E-02 9.87E-04 7.52E-04 7.22E-02 Organelle ﬁssion
GO:6461 3.01E-05 8.82E-03 2.65E-01 9.72E-03 1.41E-03 1.27E-02 2.41E-02 Protein complex assembly
GO:70271 3.01E-05 8.82E-03 2.65E-01 9.72E-03 1.41E-03 1.27E-02 2.41E-02 Protein complex biogenesis
GO:9146 3.40E-05 6.26E-03 4.10E-02 5.83E-03 4.24E-03 4.90E-02 3.30E-02 Purine nucleoside triphosphate catabolic process
GO:9203 3.40E-05 6.26E-03 4.10E-02 5.83E-03 4.24E-03 4.90E-02 3.30E-02 Ribonucleoside triphosphate catabolic process
GO:9207 3.40E-05 6.26E-03 4.10E-02 5.83E-03 4.24E-03 4.90E-02 3.30E-02 Purine ribonucleoside triphosphate catabolic process
GO:6200 3.70E-05 9.25E-04 4.10E-02 1.73E-03 2.59E-02 4.90E-02 1.24E-01 ATP catabolic process
GO:16887 3.70E-05 9.25E-04 4.10E-02 1.73E-03 2.59E-02 4.90E-02 1.24E-01 ATPase activity
GO:280 4.29E-05 5.63E-03 2.06E-01 7.10E-03 4.54E-03 9.60E-03 7.22E-02 Nuclear division
GO:7067 4.29E-05 5.63E-03 2.06E-01 7.10E-03 4.54E-03 9.60E-03 7.22E-02 Mitosis
GO:51649 4.91E-05 4.32E-04 7.35E-02 1.51E-03 3.23E-02 2.53E-02 1.17E-01 Establishment of localization in cell
GO:87 5.39E-05 1.50E-02 4.13E-01 7.10E-03 2.02E-03 9.60E-03 3.43E-02 M phase of mitotic cell cycle
GO:6936 5.55E-05 3.88E-03 4.70E-01 2.05E-03 5.93E-03 1.95E-03 6.60E-02 Muscle contraction
GO:34655 5.55E-05 4.13E-02 4.46E-01 3.20E-02 1.14E-03 1.68E-02 1.94E-02 Nucleobase-containing compound catabolic process
GO:44270 5.55E-05 4.13E-02 4.46E-01 3.20E-02 1.14E-03 1.68E-02 1.94E-02 Cellular nitrogen compound catabolic process
MGI:4811 6.15E-05 1.09E-04 4.28E-01 2.17E-05 3.97E-02 1.02E-01 1.36E-01 Abnormal neuron physiology
MGI:1876 6.18E-05 2.29E-02 4.27E-01 2.48E-02 2.09E-03 7.33E-02 1.06E-02 Decreased inﬂammatory response
GO:8610 7.81E-05 2.43E-02 2.03E-01 3.79E-02 1.52E-03 1.43E-04 6.63E-02 Lipid biosynthetic process
















































































Pathway p (Combined) p (ADHD) p (ADHD del) p (ADHD dup) p (ASD) p (ASD del) p (ASD dup) Function
GO:51656 9.17E-05 1.97E-04 N/A 1.97E-04 3.09E-02 7.33E-02 8.30E-02 Establishment of organelle localization
MGI:1756 9.69E-05 2.54E-02 4.81E-01 2.43E-02 1.29E-03 1.82E-02 1.16E-02 Abnormal urination
MGI:5278 1.01E-04 4.60E-04 4.81E-01 1.70E-04 2.15E-02 1.39E-03 2.41E-01 Abnormal cholesterol homeostasis
GO:16053 1.06E-04 3.82E-03 2.67E-01 4.33E-03 1.14E-02 1.89E-02 8.50E-02 Organic acid biosynthetic process
GO:46394 1.06E-04 3.82E-03 2.67E-01 4.33E-03 1.14E-02 1.89E-02 8.50E-02 Carboxylic acid biosynthetic process
GO:6690 1.15E-04 4.80E-02 N/A 4.80E-02 4.98E-04 7.33E-02 3.14E-03 Icosanoid metabolic process
GO:33559 1.15E-04 4.80E-02 N/A 4.80E-02 4.98E-04 7.33E-02 3.14E-03 Unsaturated fatty acid metabolic process
MGI:5294 1.15E-04 1.58E-03 N/A 1.58E-03 1.62E-02 1.21E-01 4.83E-02 Abnormal heart ventricle morphology
GO:51641 1.24E-04 1.47E-03 3.43E-01 2.03E-03 3.40E-02 5.81E-02 9.01E-02 Cellular localization
MGI:180 1.55E-04 8.00E-04 4.81E-01 3.43E-04 2.11E-02 4.89E-03 1.57E-01 Abnormal circulating cholesterol level
GO:42623 1.56E-04 1.87E-03 1.04E-01 1.73E-03 4.77E-02 1.38E-01 1.25E-01 ATPase activity, coupled
GO:279 1.95E-04 4.00E-02 2.42E-01 1.02E-02 2.50E-03 7.81E-02 9.15E-03 M phase
GO:6692 2.23E-04 4.82E-02 N/A 4.82E-02 1.15E-03 7.33E-02 6.28E-03 Prostanoid metabolic process
GO:46034 2.27E-04 1.50E-02 3.82E-01 1.19E-02 1.36E-02 3.63E-03 1.62E-01 ATP metabolic process
MGI:1663 2.70E-04 1.31E-02 6.54E-02 3.97E-02 2.03E-02 1.82E-02 9.62E-02 Abnormal digestive system physiology
GO:793 2.79E-04 2.41E-03 N/A 2.41E-03 2.62E-02 2.54E-01 1.60E-02 Condensed chromosome
KEGG4020 2.94E-04 2.23E-02 2.59E-01 9.52E-03 5.10E-03 1.33E-01 2.12E-02 Calcium signaling pathway
GO:19752 3.00E-04 1.51E-02 4.14E-01 1.23E-02 8.88E-03 3.86E-01 1.34E-02 Carboxylic acid metabolic process
GO:42180 3.00E-04 1.51E-02 4.14E-01 1.23E-02 8.88E-03 3.86E-01 1.34E-02 Cellular ketone metabolic process
GO:43436 3.00E-04 1.51E-02 4.14E-01 1.23E-02 8.88E-03 3.86E-01 1.34E-02 Oxoacid metabolic process
GO:6082 3.07E-04 9.49E-03 4.14E-01 7.07E-03 1.36E-02 3.86E-01 2.10E-02 Organic acid metabolic process
GO:43292 3.12E-04 3.91E-02 4.62E-01 5.44E-02 2.72E-03 1.95E-03 4.78E-02 Contractile ﬁber
GO:22857 3.45E-04 7.98E-03 4.05E-01 1.25E-02 2.04E-02 3.58E-03 2.71E-01 Transmembrane transporter activity
GO:775 3.81E-04 1.97E-03 4.70E-01 1.53E-03 4.10E-02 2.99E-02 1.72E-01 Chromosome, centromeric region
MGI:2462 3.85E-04 5.97E-03 4.26E-01 1.32E-02 3.62E-02 1.95E-03 3.05E-01 Abnormal granulocyte physiology
MGI:3947 4.01E-04 8.00E-04 4.81E-01 3.43E-04 4.11E-02 4.89E-03 2.41E-01 Abnormal cholesterol level
GO:7613 4.13E-04 2.69E-03 1.40E-01 1.78E-04 1.50E-02 5.06E-05 3.72E-01 Memory
GO:33036 4.43E-04 1.75E-02 7.26E-02 3.23E-02 1.38E-02 4.77E-02 9.49E-02 Macromolecule localization
MGI:8873 4.48E-04 1.01E-02 6.74E-02 3.12E-02 4.39E-02 4.82E-01 2.12E-02 Increased physiological sensitivity to xenobiotic
GO:5929 4.71E-04 1.22E-03 1.08E-01 1.48E-03 4.82E-02 5.36E-03 2.70E-01 Cilium
GO:55074 5.40E-04 4.48E-03 1.76E-01 8.83E-03 4.84E-02 4.35E-03 3.13E-01 Calcium ion homeostasis
GO:72507 5.40E-04 4.48E-03 1.76E-01 8.83E-03 4.84E-02 4.35E-03 3.13E-01 Divalent inorganic cation homeostasis
MGI:2064 5.53E-04 1.06E-02 2.68E-01 2.55E-02 2.28E-02 3.89E-03 1.70E-01 Seizures
GO:44449 5.55E-04 3.91E-02 4.62E-01 5.44E-02 5.55E-03 1.95E-03 7.75E-02 Contractile ﬁber part
MGI:2106 6.50E-04 1.72E-02 2.19E-01 1.88E-03 2.86E-02 1.64E-02 1.99E-01 Abnormal muscle physiology
GO:55085 6.77E-04 2.29E-02 3.71E-01 2.17E-02 1.76E-02 3.58E-03 2.42E-01 Transmembrane transport
GO:776 6.78E-04 3.18E-03 4.70E-01 2.88E-03 3.30E-02 2.99E-02 1.25E-01 Kinetochore
































































Pathway p (Combined) p (ADHD) p (ADHD del) p (ADHD dup) p (ASD) p (ASD del) p (ASD dup) Function
GO:43623 7.18E-04 4.36E-03 N/A 4.36E-03 2.65E-02 4.48E-02 1.39E-01 Cellular protein complex assembly
GO:71822 7.36E-04 1.89E-02 2.65E-01 2.07E-02 1.34E-02 1.27E-02 1.51E-01 Protein complex subunit organization
GO:3001 7.63E-04 9.80E-03 1.59E-01 2.36E-02 4.05E-02 1.85E-03 2.83E-01 Generation of a signal involved in cell-cell signaling
GO:23061 7.63E-04 9.80E-03 1.59E-01 2.36E-02 4.05E-02 1.85E-03 2.83E-01 Signal release
GO:42470 7.94E-04 1.16E-02 4.81E-01 8.16E-03 3.39E-02 7.33E-02 9.52E-02 Melanosome
GO:48770 7.94E-04 1.16E-02 4.81E-01 8.16E-03 3.39E-02 7.33E-02 9.52E-02 Pigment granule
GO:5261 9.70E-04 2.03E-02 4.18E-01 3.04E-02 1.83E-02 1.30E-05 3.78E-01 Cation channel activity
GO:5694 1.12E-03 1.19E-02 4.73E-01 6.90E-03 4.24E-02 6.98E-02 1.66E-01 Chromosome
GO:48878 1.20E-03 2.04E-02 3.38E-01 1.69E-02 4.10E-02 1.88E-02 2.57E-01 Chemical homeostasis
GO:42803 1.21E-03 8.65E-03 1.08E-01 1.06E-03 4.66E-02 7.80E-04 4.00E-01 Protein homodimerization activity
GO:5215 1.32E-03 2.76E-02 3.73E-01 3.46E-02 3.27E-02 8.29E-03 3.08E-01 Transporter activity
GO:7601 1.42E-03 2.04E-02 3.02E-01 2.37E-02 3.00E-02 3.49E-03 2.12E-01 Visual perception
GO:44283 2.00E-03 2.33E-02 2.66E-01 1.90E-02 3.33E-02 6.84E-03 2.65E-01 Small molecule biosynthetic process
GO:6631 2.10E-03 1.76E-02 2.69E-01 1.26E-02 3.61E-02 3.23E-01 6.73E-02 Fatty acid metabolic process
MGI:6042 2.22E-03 2.39E-02 3.33E-01 2.60E-02 3.13E-02 1.45E-04 4.90E-01 Increased apoptosis
GO:44085 2.44E-03 1.42E-02 4.24E-01 1.76E-02 2.00E-02 2.83E-02 1.33E-01 Cellular component biogenesis
GO:32787 2.46E-03 1.76E-02 2.69E-01 1.26E-02 2.81E-02 1.23E-01 8.62E-02 Monocarboxylic acid metabolic process
GO:30030 2.84E-03 3.37E-02 2.89E-01 4.46E-02 4.19E-02 4.34E-03 3.15E-01 Cell projection organization
GO:6935 3.68E-03 4.22E-02 1.11E-01 4.87E-02 4.03E-02 3.70E-03 2.93E-01 Chemotaxis
GO:42330 3.68E-03 4.22E-02 1.11E-01 4.87E-02 4.03E-02 3.70E-03 2.93E-01 Taxis
GO:65003 3.69E-03 2.93E-02 2.65E-01 2.64E-02 2.23E-02 1.02E-01 6.84E-02 Macromolecular complex assembly
GO:43279 4.69E-03 2.31E-02 1.85E-01 7.25E-03 4.21E-02 1.55E-02 1.70E-01 Response to alkaloid
GO:22607 5.06E-03 2.98E-02 4.86E-01 2.71E-02 2.29E-02 2.82E-02 1.48E-01 Cellular component assembly
MGI:3203 7.57E-03 4.01E-02 4.31E-01 1.58E-02 4.45E-02 4.01E-03 2.41E-01 Increased neuron apoptosis
MGI:1402 7.81E-03 2.22E-02 1.83E-01 2.45E-03 4.31E-02 1.25E-01 1.69E-01 Hypoactivity





























































































Genes in Top 3
Pathways All Genes Hit by CNV
ASD 1 2678023 3198235 Dup Inherited No No ACTRT2, PRDM16,
ASD 1 30334653 30951250 Del Inherited No No




ZBTB8B, ZBTB8A, ZBTB8OS, RBBP4,
SYNC, KIAA1522, YARS, S100PBP,
FNDC5, HPCA, TMEM54,
RNF19B, AK2,
ASD 1 57997961 58568421 Dup Inherited No No DAB1,





RHOC, CAPZA1, MOV10, RHOC, PPM1J,
FAM19A3, LOC128322, SLC16A1,
LRIG2,
ASD 1 144099494 144627859 Del Inherited No No GO:42493, MGI:5620, GO:48285,
GO:5794,
TXNIP, PDZK1, HFE2, TXNIP, POLR3GL, ANKRD34A,
LIX1L, RBM8A, PEX11B, ITGA10,
ANKRD35, PIAS3, NUDT17,
POLR3C, RNF115, CD160, PDZK1,
GPR89A, GPR89C,




PRKAB2, FMO5, CHD1L, BCL9,
ACP6, GJA5, GJA8, GPR89B,
NBPF24,
ASD 1 155976899 156525831 Dup Inherited No No FCRL2, FCRL1, CD5L, KIRREL,
CD1D, CD1A,
ASD 1 240371271 241192975 Del Inherited No No PLD5,
ASD 1 244036261 245191978 Del Inherited No No GO:5794, GO:48285, GO:51301,
GO:6461,
AHCTF1 , SMYD3, TFB2M, CNST, SCCPDH,
LOC100130097, AHCTF1,
ASD 2 20961443 21478579 Dup Inherited No No APOB, LOC100129278,
ASD 2 32480121 33184723 Dup Inherited No Yes BIRC6, TTC27, LTBP1,
ASD 2 32480121 33174461 Dup Inherited No Yes BIRC6, TTC27, LTBP1,
ASD 2 32483938 33181898 Dup Inherited No Yes BIRC6, TTC27, LTBP1,
ASD 2 89685181 90970848 Del Inherited No No IGK@,
ASD 2 110050606 110615080 Dup Inherited No No GO:5794, MALL, NPHP1,













































































Genes in Top 3
Pathways All Genes Hit by CNV
ASD 2 171063444 171826719 Dup Inherited No No PAN-PW:44, GO:42493, GO:5794, MYO3B, GAD1, MYO3B, SP5, ERICH2, GAD1,
GORASP2, TLK1,
ASD 2 182777089 184116208 Dup Inherited No No GO:5516, PDE1A, DNAJC10, FRZB, NCKAP1,
DUSP19, NUP35,
ASD 3 227344 1486108 Dup Inherited No Yes CHL1, CNTN6,
ASD 3 464181 1251877 Dup Inherited No Yes CNTN6,
ASD 3 2365612 2875100 Del Inherited Yes No CNTN4,
ASD 3 38475193 39565199 Dup Inherited No No MGI:5620, GO:42493, GO:5794,
GO:48285, GO:10927,
SCN11A , ACVR2B, EXOG, SCN5A, SCN10A,
SCN11A, WDR48, GORASP1,
TTC21A, CSRNP1, XIRP1, DSTNP4,
CX3CR1, CCR8, SLC25A38,
RPSA, MOBP,
ASD 3 73185165 73722969 Dup Inherited No No PPP4R2, EBLN2, PDZRN3,
ASD 3 97474308 98204406 Dup Inherited No Yes EPHA6,
ASD 3 100079301 100925499 Dup Inherited No No DCBLD2, COL8A1,
ASD 3 112120161 112961027 Del Inherited No No PVRL3, CD96, ZBED2, PLCXD2,
ASD 3 165273764 165817130 Del Inherited No No
ASD 4 34802932 35676439 Dup Inherited No No
ASD 4 76098820 76815811 Dup Inherited No Yes GO:5794, PARM1, RCHY1, THAP6, C4orf26,
CDKL2, G3BP2,
ASD 4 115072154 115794717 Dup Inherited No No ARSJ, UGT8,
ASD 4 162009237 162934619 Dup Inherited No No FSTL5,
ASD 4 185835398 186412560 Dup Inherited No No GO:48285, CCDC111, MLF1IP, ACSL1,
LOC100129240, HELT, SLC25A4,
KIAA1430, SNX25,
ASD 4 188554375 189071169 Dup Inherited No No
ASD 4 188698152 189493792 Dup Inherited No No ZFP42, TRIML2, TRIML1,
ASD 4 189533070 190718765 Del Inherited No Yes
ASD 5 12454130 12960694 Del Inherited No No
ASD 5 19532212 20357961 Del Inherited No No CDH18,
ASD 5 25659711 26168705 Del Inherited No No
ASD 5 89477076 90142864 Dup Inherited No No GO:51301, GO:48285, CETN3, CETN3, MBLAC2, POLR3G, LYSMD3,
GPR98,
ASD 5 104047191 104600670 Del Inherited No No




























































































es in Top 3
athways All Genes Hit by CNV
ASD 5 110263975 110789999 Dup Inherited No No GO:5516, TSLP, WDR36, CAMK4,
ASD 5 125084106 126044143 Dup Inherited No No
ASD 6 7076523 7622856 Dup Inherited No No
ASD 6 57336322 58188685 Dup Inherited No No




ASD 7 61649656 62372905 Dup Inherited No No
ASD 7 61667556 62336389 Dup Inherited No No
ASD 7 61681059 62336389 Dup Inherited No No
ASD 7 61681059 62336389 Dup Inherited No No
ASD 7 87986401 89721065 Dup Inherited No No GO:5794,
ASD 7 88690424 89260572 Dup Inherited No No
ASD 7 88697197 89260572 Dup Inherited No No
ASD 7 108956186 109951683 Dup Inherited No No
ASD 7 142981711 143506472 Dup Inherited No No
ASD 8 2334306 3290879 Dup Inherited No No
ASD 8 18617115 19445855 Dup Inherited No Yes GO:5794,
ASD 8 18774097 19556817 Dup Inherited No Yes GO:5794,
ASD 8 89476937 90298110 Dup Inherited No Yes
ASD 8 124683548 125559395 Del Inherited No No
ASD 9 92645 733353 Dup Inherited No No


































































RREB1, SSR1, CAGE1, RIOK1,
LOC644058, DSP, SNRNP48,
PRIM2,































Genes in Top 3
Pathways All Genes Hit by CNV
ASD 9 29908652 30428383 Del Inherited No No
ASD 9 72482886 73063512 Del Inherited No No TRPM3,






ASD 10 44956873 45478525 Dup Inherited No No GO:6633, OR13A1, ALOX5, MARCH-8,
ZFAND4,
ASD 10 134676107 135272450 Dup Inherited No No GO:6461, GO:51301, SYCE1, GPR123, KNDC1, UTF1, VENTX,
ADAM8, LOC100128697,
TUBGCP2, ZNF511, CALY, PRAP1,
FUOM, ECHS1, PAOX, MTG1,
SPRN, CYP2E1, SYCE1,
ASD 11 9978367 10670008 Del Inherited No No GO:6461, MGI:5620, GO:9154,
GO:6195, GO:9261, GO:9166,
SBF2, ADM, AMPD3, RNF141,
LYVE1, MRVI1,
ASD 11 48332180 48914233 Del Inherited No No OR4A47,
ASD 11 89389893 91075549 Dup Inherited No No UBTFL1, NAALAD2, CHORDC1,





AACS, TMED2, DDX55, EIF2B1, GTF2H3,
TCTN2, ATP6V0A2, DNAH10,
CCDC92, ZNF664, FAM101A,
NCOR2, SCARB1, UBC, DHX37,
BRI3BP, AACS, LOC100129380,
TMEM132B,
ASD 14 26685418 28245016 Dup Inherited No No
ASD 15 20303106 20836955 Del Inherited No No TUBGCP5, CYFIP1, NIPA2, NIPA1,
ASD 15 20303106 20807351 Dup Inherited No No TUBGCP5, CYFIP1, NIPA2, NIPA1,


































































































Genes in Top 3
Pathways All Genes Hit by CNV
ASD 15 26887815 28157206 Dup Inherited No Yes GO:5794, APBA2, NDNL2, TJP1,




ASD 15 29762552 30302973 Dup Inherited No Yes PAN-PW:44, CHRNA7 , LOC100130857, CHRNA7,
ASD 15 29780769 30303265 Dup Inherited No Yes PAN-PW:44, CHRNA7 , LOC100130857, CHRNA7,
ASD 15 29792536 30303265 Dup Inherited No Yes PAN-PW:44, CHRNA7 , LOC100130857, CHRNA7,
ASD 15 34016557 34695083 Del Inherited No No
ASD 16 5312482 5968452 Dup Inherited No No
ASD 16 7787398 8567137 Dup Inherited No No TMEM114,










NOMO1, NPIP, PDXDC1, NTAN1,
RRN3, MPV17L, C16orf45,
KIAA0430, NDE1, MYH11, FOPNL,
ABCC1, ABCC6, NOMO3,











NDE1, MYH11, FOPNL, ABCC1,
ABCC6, NOMO3,

























































































Genes in Top 3
Pathways All Genes Hit by CNV
ASD 16 21788416 22351124 Del Inherited No Yes GO:5516, 61E3.4, UQCRC2, PDZD9,
C16orf52, VWA3A, EEF2K,
POLR3E, CDR2,
ASD 16 29502984 30127026 Dup Inherited Yes Yes GO:6461, GO:5794, GO:48285,
GO:42493, GO:9205, GO:9144,
GO:9199, GO:9141,
MVP, SPN, QPRT, C16orf54, ZG16, KIF22,




FAM57B, ALDOA, PPP4C, TBX6,
YPEL3, GDPD3, MAPK3, CORO1A,
BOLA2B, SLX1A, SULT1A3,
ASD 16 60027157 61668976 Del Inherited No No CDH8,
ASD 16 80739109 82225301 Dup Inherited No No MPHOSPH6, CDH13,




WFDC1, DNAAF1, TAF1C, ADAD2, KCNG4,
WFDC1, ATP2C2, KIAA1609,
COTL1, KLHL36, USP10,
ASD 17 2852848 3536216 Dup Inherited No No GO:5516, GO:9205, GO:9144,
GO:9199, GO:9141,
RAP1GAP2, OR1D5, OR1D2,
OR1G1, OR1A2, OR1A1, OR3A2,
OR3A1, OR1E1, OR3A3, OR1E2,
SPATA22, ASPA, TRPV3, TRPV1,
SHPK, CTNS, TAX1BP3, EMC6,
P2RX5,
ASD 17 14040467 15423806 Del Inherited No No GO:48285, GO:6461, GO:5794,
GO:10927,
COX10, CDRT15, HS3ST3B1,
PMP22, TEKT3, CDRT4, TVP23C,
ASD 17 48424668 49111866 Dup Inherited No No


































































































Genes in Top 3
Pathways All Genes Hit by CNV




CHMP1B , PIEZO2, SLC35G4, GNAL,
CHMP1B, MPPE1,




CHMP1B , SLC35G4, GNAL, CHMP1B,
MPPE1, IMPA2,
ASD 18 66234261 66907023 Dup Inherited No No
ASD 18 69788042 70538070 Dup Inherited No No FBXO15, TIMM21, CYB5A,
C18orf63, FAM69C, CNDP2,
CNDP1, ZNF407,
ASD 19 32455280 32988248 Dup Inherited No Yes




SIRPA, PDYN, STK35, TGM3, TGM6,
SNRPB, ZNF343, TMC2,
ASD 20 5250653 5767545 Dup Inherited No No GPCPD1, C20orf196,




USP41, ZNF74, SCARF2, KLHL22,
MED15, PI4KA, SERPIND1,
SNAP29, CRKL, AIFM3, LZTR1,
THAP7, P2RX6, SLC7A4,




USP41, ZNF74, SCARF2, KLHL22,
MED15, PI4KA, SERPIND1,
SNAP29, CRKL, AIFM3, LZTR1,
THAP7, P2RX6, SLC7A4,




ZNF74, SCARF2, KLHL22, MED15,
PI4KA, SERPIND1, SNAP29, CRKL,
AIFM3, LZTR1, THAP7, P2RX6,
SLC7A4,


















































































Genes in Top 3
Pathways All Genes Hit by CNV




ASD 22 22641474 23323367 Dup Inherited No No GO:6633, GO:51301, SPECC1L, DDTL, DDT, GSTT2, LOC391322,




ASD 22 47780315 48387485 Dup Inherited No No
ASD 22 47780315 48387485 Dup Inherited No No
ASD 23 3702747 4567265 Dup Inherited No No LOC729162,
ASD 23 6456825 8095053 Dup Inherited No No GO:5794, VCX3A, HDHD1, STS, VCX, PNPLA4,
ASD 23 6456825 8095053 Dup Inherited No No GO:5794, VCX3A, HDHD1, STS, VCX, PNPLA4,
ASD 23 9931816 10758861 Dup Inherited No No WWC3, CLCN4, MID1,
ASD 23 24087361 24612313 Dup Inherited No No ZFX, SUPT20HL2, SUPT20HL1, PDK3,
PCYT1B,
ASD 23 28931559 29478966 Dup Inherited No No IL1RAPL1,
ASD 23 88052525 88616963 Del Inherited No No
ASD 23 139846520 141067065 Dup Inherited No No SPANXB2, SPANXB1, LDOC1,
SPANXC, SPANXA1, SPANXA2,
SPANXD, MAGEC3, MAGEC1,
ASD 23 148075334 148617551 Dup Inherited No No IDS, CXorf40A, MAGEA9B, HSFX2,
TMEM185A, MAGEA11,
ASD 7 61100583 62082083 Dup Denovo No No
ASD 8 704383 1521910 Dup Denovo No No DLGAP2,
ASD 8 65354366 66254869 Del Denovo No No GO:42493, CYP7B1 , BHLHE22, CYP7B1,
ASD 8 66140254 66753892 Del Denovo No No ARMC1, MTFR1,




VLDLR, FOXD4, CBWD1, C9orf66, DOCK8,































































































Genes in Top 3
Pathways All Genes Hit by CNV














FAM69B, LCN10, LCN6, LCN8,
LCN15, TMEM141, KIAA1984,
RABL6, C9orf172, PHPT1,
MAMDC4, EDF1, TRAF2, FBXW5,
C8G, LCN12, PTGDS, LCNL1,
C9orf142, CLIC3, ABCA2,
C9orf139, FUT7, NPDC1, ENTPD2,
SAPCD2, UAP1L1, MAN1B1, DPP7,




COBRA1, TOR4A, NRARP, EXD3,









NOTCH1, EGFL7, AGPAT2, FAM69B,
LCN10, LCN6, LCN8, LCN15,
TMEM141, KIAA1984, RABL6,
C9orf172, PHPT1, MAMDC4,
EDF1, TRAF2, FBXW5, C8G,
LCN12, PTGDS, LCNL1, C9orf142,
CLIC3, ABCA2, C9orf139, FUT7,
NPDC1, ENTPD2, SAPCD2,
UAP1L1, MAN1B1, DPP7, GRIN1,

















































































Genes in Top 3
Pathways All Genes Hit by CNV











METTL7B, ITGA7, BLOC1S1, RDH5,
CD63, GDF11, SARNP, ORMDL2,
DNAJC14, MMP19, WIBG, DGKA,
PMEL, CDK2, RAB5B, SUOX, IKZF4,
RPS26, ERBB3, PA2G4, RPL41,
ZC3H10, ESYT1, MYL6B, MYL6,
SMARCC2, RNF41, NABP2,
SLC39A5, ANKRD52, COQ10A,
CS, CNPY2, PAN2, IL23A, STAT2,
APOF, TIMELESS, MIP, SPRYD4,
GLS2, RBMS2, BAZ2A, ATP5B,
PTGES3, NACA, PRIM1, HSD17B6,
SDR9C7, RDH16, GPR182,
ZBTB39, TAC3, MYO1A,
TMEM194A, NAB2, STAT6, LRP1,
NXPH4, SHMT2, NDUFA4L2,
STAC3, R3HDM2, INHBC, INHBE,
GLI1, ARHGAP9, MARS, DDIT3,





TSFM, AVIL, CTDSP2, XRCC6BP1,
LRIG3, SLC16A7,




GABRG3 , GOLGA6L2, MKRN3, MAGEL2,
































































































Genes in Top 3
Pathways All Genes Hit by CNV
ASD 16 29502984 30210849 Dup Denovo Yes Yes GO:6461, GO:5794, GO:48285,
GO:42493, GO:9205, GO:9144,
GO:9199, GO:9141,
MVP, SPN, QPRT, C16orf54, ZG16, KIF22,




FAM57B, ALDOA, PPP4C, TBX6,
YPEL3, GDPD3, MAPK3, CORO1A,
BOLA2B, SLX1A, SULT1A3,
ASD 16 29502984 30127026 Del Denovo Yes Yes GO:6461, GO:5794, GO:48285,
GO:42493, GO:9205, GO:9144,
GO:9199, GO:9141,
MVP, SPN, QPRT, C16orf54, ZG16, KIF22,




FAM57B, ALDOA, PPP4C, TBX6,
YPEL3, GDPD3, MAPK3, CORO1A,
BOLA2B, SLX1A, SULT1A3,
ASD 16 29554843 30195224 Del Denovo Yes Yes GO:6461, GO:5794, GO:48285,
GO:42493, GO:9205, GO:9144,
GO:9199, GO:9141,
MVP, SPN, QPRT, C16orf54, ZG16, KIF22,




FAM57B, ALDOA, PPP4C, TBX6,
YPEL3, GDPD3, MAPK3, CORO1A,
BOLA2B, SLX1A, SULT1A3,











CCDC137, ARL16, HGS, MRPL12,
SLC25A10, PPP1R27, P4HB,
ARHGDIA, ALYREF, ANAPC11,
NPB, PCYT2, SIRT7, MAFG, PYCR1,
MYADML2, NOTUM, ASPSCR1,
STRA13, LRRC45, RAC3, DCXR,














































































Genes in Top 3
Pathways All Genes Hit by CNV
ADHD 1 5198919 5747986 Dup Unknown No No
ADHD 1 5220394 5754188 Dup Unknown No No
ADHD 1 53772097 54338898 Dup Unknown No No GO:6461, GO:5794, GLIS1, TMEM48, YIPF1, DIO1,
HSPB11, LRRC42, LDLRAD1,
TMEM59, TCEANC2,




PRKAB2, FMO5, CHD1L, BCL9,
ACP6, GJA5, GJA8, GPR89B,
NBPF24,
ADHD 1 159732044 160485312 Del Unknown No No GO:5794, FCGR2A, HSPA6, FCGR3A, FCGR2C,
FCGR3B, FCGR2B, FCRLA, FCRLB,
DUSP12, ATF6, OLFML2B,
NOS1AP,
ADHD 1 235967993 237757467 Dup Unknown No No GO:5516, MGI:5620, RYR2, ZP4,
ADHD 1 245714416 246522135 Del Unknown No No OR2W5, OR2C3, GCSAML, OR2G2,
OR2G3, OR13G1, OR6F1,
OR1C1, OR14A16, OR11L1,
TRIM58, OR2W3, OR2T8, OR2L13,
OR2L8, OR2AK2, OR2L5, OR2L2,
OR2L3, OR2M5, OR2M2, OR2M3,
OR2M4, OR2T33,
ADHD 2 32487194 33181898 Dup Unknown No Yes BIRC6, TTC27, LTBP1,
ADHD 2 32497032 33181898 Dup Unknown No Yes BIRC6, TTC27, LTBP1,
ADHD 2 106690781 108292465 Dup Unknown No No GO:5794, ST6GAL2, RGPD4, SLC5A7,
SULT1C3, SULT1C2,
ADHD 2 107907419 109818614 Del Unknown No No GO:5794, GO:48285, GO:51301, SEPT-10, SLC5A7, SULT1C3, SULT1C2,
SULT1C4, GCC2, LIMS1, RANBP2,
CCDC138, EDAR, SH3RF3, SEPT-
10, SOWAHC,
ADHD 2 128985135 129881989 Del Unknown No No
ADHD 2 153846483 154652950 Dup Unknown No No GO:5794, RPRM, GALNT13,
ADHD 3 849785 1451706 Dup Unknown No Yes CNTN6,
ADHD 3 1166638 2183832 Dup Unknown Yes Yes CNTN6, CNTN4,
ADHD 3 2969491 4461303 Del Unknown Yes No GO:9154, GO:9205, GO:6195,
GO:9143, GO:9144, GO:9261,
GO:9199, GO:9166, GO:9141,






























































































Genes in Top 3
Pathways All Genes Hit by CNV
ADHD 3 3999657 4922174 Dup Unknown Yes No SETMAR, SUMF1, ITPR1,
ADHD 3 32039611 33903472 Dup Unknown No No GO:51301, GO:48285, GO:5794, DYNC1LI1,
CLASP2 ,
PDCD6IP,
GPD1L, CMTM8, CMTM7, CMTM6,
DYNC1LI1, CNOT10, TRIM71,
CCR4, GLB1, TMPPE, CRTAP,
SUSD5, FBXL2, UBP1, CLASP2,
PDCD6IP,
ADHD 3 96242194 98639625 Dup Unknown No Yes EPHA6,
ADHD 3 174547344 176016137 Dup Unknown Yes No GO:6461, NLGN1,
ADHD 3 193473269 194025326 Dup Unknown No No FGF12, MB21D2,
ADHD 4 18233904 19901337 Dup Unknown No No SLIT2,





ANAPC4 , LOC729175, DHX15, SOD3,
CCDC149, LGI2, SEPSECS, PI4K2B,
ZCCHC4, ANAPC4, SLC34A2,
SEL1L3, C4orf52, RBPJ, CCKAR,
TBC1D19, STIM2,
ADHD 4 26350218 27635050 Dup Unknown No No TBC1D19, STIM2,
ADHD 4 65791505 66605654 Del Unknown No No EPHA5,
ADHD 4 71457385 72257388 Dup Unknown No No AMBN, ENAM, IGJ, UTP3, RUFY3,
GRSF1, MOB1B, DCK,
ADHD 4 75931128 77058132 Dup Unknown No Yes GO:5794, BTC, PARM1, RCHY1, THAP6,
C4orf26, CDKL2, G3BP2, USO1,
PPEF2, NAAA,




ABCG2, ABCG2, PPM1K, HERC6, HERC5,
PIGY, HERC3, NAP1L5, FAM13A,
LOC731282, TIGD2, GPRIN3,
ADHD 4 184952586 185493309 Dup Unknown No No STOX2, ENPP6, LOC391722,
ADHD 4 189649974 190598641 Del Unknown No Yes
ADHD 6 122085305 122622855 Dup Unknown No No
ADHD 7 17811400 18312755 Dup Unknown No No SNX13, PRPS1L1,
ADHD 7 69777660 71572992 Dup Unknown Yes No GO:5794, AUTS2, WBSCR17, CALN1,















































































Genes in Top 3
Pathways All Genes Hit by CNV
ADHD 8 5374826 6304573 Del Unknown No No MCPH1,
ADHD 8 9082416 9659969 Dup Unknown No No GO:5794, TNKS,
ADHD 8 18578565 19386565 Dup Unknown No Yes GO:5794, PSD3, SH2D4A, CSGALNACT1,
ADHD 8 43143782 43910848 Dup Unknown No No GO:6461, HGSNAT, POTEA,
ADHD 8 85438801 88424995 Del Unknown No No GO:51301, GO:48285, GO:5794,
MGI:5620,
LRRCC1 , RALYL, LRRCC1, E2F5, C8orf59,
CA13, CA1, CA3, CA2, REXO1L1,
PSKH2, ATP6V0D2, SLC7A13,
WWP1, FAM82B, CPNE3, CNGB3,
CNBD1,
ADHD 8 89227035 90419753 Dup Unknown No Yes MMP16,












ERCC6, PGBD3, CHAT, SLC18A3,
C10orf53, OGDHL,
ADHD 11 5582423 7488751 Del Unknown No No GO:6461, GO:5794, GO:42493,
GO:10927,








CCKBR, PRKCDBP, SMPD1, APBB1,
HPX, TRIM3, ARFIP2, TIMM10B,


































































































Genes in Top 3
Pathways All Genes Hit by CNV








GAL, CPT1A, LRP5, PPP6R3, GAL, MTL5, CPT1A,
MRPL21, IGHMBP2, MRGPRD,
TPCN2, MYEOV,




DYNC2H1, PDGFD, DDI1, CASP4,




ADHD 11 133553353 134382876 Dup Unknown No No GO:51301, GO:48285, GO:5794, NCAPD3 , NCAPD3, VPS26B, THYN1, ACAD8,
GLB1L3, GLB1L2, B3GAT1,
ADHD 12 28812958 29402567 Dup Unknown No No GO:5794, FAR2, ERGIC2,
ADHD 12 33175713 33809963 Del Unknown No No SYT10,
ADHD 12 34122001 34711193 Dup Unknown No No
ADHD 13 22494127 23860983 Dup Unknown No No SGCG, SACS, TNFRSF19, MIPEP,
C1QTNF9B-AS1, C1QTNF9B,
SPATA13, C1QTNF9,
ADHD 13 63330923 63886321 Del Unknown No No
ADHD 14 92009962 92767834 Dup Unknown No No GO:5794, SLC24A4, RIN3, LGMN, GOLGA5,
CHGA, ITPK1, MOAP1, TMEM251,
C14orf142, UBR7,




GABRG3 , LOC440243, GOLGA6L2, MKRN3,
MAGEL2, NDN, NPAP1, SNRPN,
SNURF, UBE3A, ATP10A, GABRB3,
GABRA5, GABRG3, OCA2,
ADHD 15 27000239 28153539 Dup Unknown No Yes GO:5794, APBA2, NDNL2, TJP1,
ADHD 15 29722573 30302218 Dup Unknown No Yes PAN-PW:44, CHRNA7 , OTUD7A, LOC100130857,
CHRNA7,














































































Genes in Top 3
Pathways All Genes Hit by CNV
ADHD 15 29722573 30302218 Dup Unknown No Yes PAN-PW:44, CHRNA7 , OTUD7A, LOC100130857,
CHRNA7,
ADHD 15 29722573 30302218 Dup Unknown No Yes PAN-PW:44, CHRNA7 , OTUD7A, LOC100130857,
CHRNA7,
ADHD 15 29734334 30302218 Dup Unknown No Yes PAN-PW:44, CHRNA7 , OTUD7A, LOC100130857,
CHRNA7,
ADHD 15 29734334 30302218 Dup Unknown No Yes PAN-PW:44, CHRNA7 , OTUD7A, LOC100130857,
CHRNA7,
ADHD 15 30688712 32587887 Dup Unknown No No MGI:5620, GO:5794, ARHGAP11A, SCG5, GREM1,
FMN1, RYR3, AVEN, CHRM5,
EMC7, PGBD4, KATNBL1, EMC4,
SLC12A6, NOP10, C15orf55,
LPCAT4, GOLGA8A,
ADHD 15 30713368 32447708 Del Unknown No No MGI:5620, ARHGAP11A, SCG5, GREM1,
FMN1, RYR3, AVEN, CHRM5,
EMC7, PGBD4, KATNBL1, EMC4,
SLC12A6, NOP10, C15orf55,
LPCAT4,
ADHD 15 31406234 31913133 Dup Unknown No No MGI:5620, RYR3,
ADHD 15 82183518 82749322 Dup Unknown No No ADAMTSL3, GOLGA6L4,










PDXDC1, NTAN1, RRN3, MPV17L,
C16orf45, KIAA0430, NDE1,
MYH11, FOPNL, ABCC1, ABCC6,










PDXDC1, NTAN1, RRN3, MPV17L,
C16orf45, KIAA0430, NDE1,





























































































Genes in Top 3
Pathways All Genes Hit by CNV











NDE1, MYH11, FOPNL, ABCC1,
ABCC6, NOMO3, XYLT1,











NDE1, MYH11, FOPNL, ABCC1,
ABCC6,











NDE1, MYH11, FOPNL, ABCC1,
ABCC6,











NDE1, MYH11, FOPNL, ABCC1,
ABCC6,

























































































Genes in Top 3
Pathways All Genes Hit by CNV











NDE1, MYH11, FOPNL, ABCC1,
ABCC6,
ADHD 16 21851681 22651534 Del Unknown No Yes GO:5516, UQCRC2, PDZD9, C16orf52,
VWA3A, EEF2K, POLR3E, CDR2,
LOC100132247,
ADHD 16 26396505 27321840 Dup Unknown No No C16orf82, KDM8, NSMCE1, IL4R,
IL21R,




MVP, SEPT-1 , SPN, QPRT, C16orf54, ZG16, KIF22,




FAM57B, ALDOA, PPP4C, TBX6,
YPEL3, GDPD3, MAPK3, CORO1A,
BOLA2B, SLX1A, SULT1A3,
CD2BP2, TBC1D10B, MYLPF,
SEPT-1, ZNF48, ZNF771, DCTPP1,
SEPHS2,





SHCBP1, VPS35, ORC6, MYLK3,
C16orf87, GPT2, DNAJA2, NETO2,
ITFG1, PHKB, ABCC12, ABCC11,
LONP2, SIAH1, N4BP1, CBLN1,
LOC100130314, C16orf78,
ADHD 16 85987740 86536663 Del Unknown No No MAP1LC3B, ZCCHC14, JPH3,
KLHDC4, SLC7A5, CA5A,






























































































Genes in Top 3
Pathways All Genes Hit by CNV







ZNHIT3, MYO19, PIGW, GGNBP2,











MYO19, PIGW, GGNBP2, DHRS11,













ADHD 19 23164768 23816927 Dup Unknown No No ZNF91, ZNF675, ZNF681,
ADHD 19 32615675 33220146 Del Unknown No Yes
ADHD 20 12795614 14242196 Dup Unknown No No GO:6461, SPTLC3, ISM1, TASP1, ESF1,
NDUFAF5, SEL1L2, MACROD2,










DGCR2, DGCR14, TSSK2, GSC2,
SLC25A1, CLTCL1, HIRA, MRPL40,
C22orf39, UFD1L, CDC45, CLDN5,






USP41, ZNF74, SCARF2, KLHL22,
MED15, PI4KA, SERPIND1,
SNAP29, CRKL, AIFM3, LZTR1,
THAP7, P2RX6, SLC7A4,
Note: This table includes the CNV type (deletion or duplication), inheritance status (inherited or de novo), where known, and whether the CNV overlaps known autism regions or case CNVs from the other disorder.
The contribution of the CNVs to the top 20 pathways from Table 2 is shown, as are the genes that they hit. del ¼ deletion; dup ¼ duplication.
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